Samsung beats pharma to develop first EU-approved Enbrel biosimilar
January 18, 2016Manufacturing and Production Benepali, CHMP, EMA, Enbrel, Samsung, Samsung Bioepis, etanercept, positive opinion
Samsung Bioepis – the collaboration between Samsung Biologics and Biogen Idec, has become the first company to have a biosimilar …
FDA criticised for safety data flaws
January 18, 2016Sales and Marketing FDA, US Government Accountability Office, pharmacovigilance, post-marketing data, safety
The US FDA is failing to meet its ‘statutorily required’ obligations to track safety data for drugs post-marketing and publish …
Two new US approvals for Novartis’ Cosentyx
January 18, 2016Research and Development, Sales and Marketing Cosentyx, Novartis
Novartis has won FDA approval for Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing …
Blow for Eleven Biotherapeutics as eye drug fails in late-stage trial
January 18, 2016Research and Development, Sales and Marketing Eleven Biotherapeutics, allergic conjunctivitis, isunakinra
A study by Eleven Biotherapeutics to prove the clinical value of its eye drug isunakinra has flopped, after the drug …
Man left brain dead after clinical trial dies in hospital
January 18, 2016Research and Development, Sales and Marketing Bial, Biotrial, clinical trial
A man left brain dead after a clinical trial in France has died in hospital and five remain in a …
MSD sues German Merck for using name in US
January 15, 2016Medical Communications, Sales and Marketing MSD, Merck
MSD says it is filing a lawsuit against the German company Merck “regarding their improper use of the name ‘Merck’ …
Clinical trial accident leaves six critical, one ‘brain dead’
January 15, 2016Medical Communications, Research and Development France, clinical trial
Six patients have been left in a critical condition following a serious accident in a clinical trial at a French …
What could artificial intelligence mean for pharma?
January 15, 2016Medical Communications artificial intelligence, digital, digital pharma, medical technology, medtech, tech
With ever rising costs in research and development, the frustratingly long time spent in bringing new novel drugs to market …
Sanofi Pasteur to join the Human Vaccines Project
January 15, 2016Medical Communications, Research and Development Human Vaccines Project, Sanofi Pasteur, vaccines
Sanofi Pasteur has become the latest pharma company to add funding to The Human Vaccines Project – a non-profit public-private …
Takeda to bring UK salesforce in-house
January 15, 2016Medical Communications, Sales and Marketing Takeda, field sales, marketing, sales, sales reps, salesforce
Takeda UK is to bring all of its sales teams and support resources in-house and reintegrate its field salesforce into …
AbbVie replaces retiring VP of Western Europe and Canada
January 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Esteban Plata, Pascale Richetta
AbbVie has appointed Esteban Plata as vice president of Western Europe and Canada.He replaces Pascale Richetta who is retiring from …
Patient involvement ‘would improve medicines R&D’
January 15, 2016Medical Communications, Research and Development EUPATI, Patient and Public Involvement, R&D
A new study has revealed a belief among pharma industry executives that greater involvement of patients and the public could …
Wave Healthcare Communications – Four predictions for med ed in 2016
January 14, 2016Medical Communications medical education
These are some of the trends Wave foresees in the forthcoming year: Integration We predict there will be a greater …
FDA says no to BioMarin’s Duchenne Muscular Dystrophy drug
January 14, 2016Medical Communications, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, FDA, Kyndrisa, drisapersen
The FDA has rejected BioMarin’s Duchenne Muscular Dystrophy (DMD) drug Kyndrisa, saying there was not enough evidence that the drug …
Pfizer may sell off Hospira unit for $2 billion
January 14, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Hospira, Pfizer, injectables, pumps
Pfizer is reportedly considering selling Hospira’s infusion pump business for around $2 billion, having acquired the injectable drugs and infusion …
US Federal Trade Commission clamps down on pharma ‘pay to delay’ deals
January 14, 2016Manufacturing and Production, Sales and Marketing Pay to delay, US Supreme Court, antitrust laws, federal trade commission, generic competition, generics, patents, pay for delay
Pharma companies were able to negotiate far fewer so-called ‘pay to delay’ cases as a strategy to stave off generic …
Takeda in myeloma research drive
January 14, 2016Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma
Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …
A brighter future for the Cancer Drugs Fund?
January 14, 2016Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Prostate Cancer UK
In November 2015, NICE and NHS England announced proposed changes to the operation of the Cancer Drugs Fund. This is …
Illumina forms spin-off to develop cancer detection test
January 14, 2016Research and Development Cancer, Illumina, cancer detection, gene sequencing, liquid biospy, oncology
Global gene sequencing company Illumina has won over $100 million in investment from high-profile investors, to create a company “to …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
